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This work describes a new nanotechnology-based immobilization strategy for cytochrome 
P450s (CYPs), the major class of drug metabolizing enzymes. Immobilization of CYPs on 
solid supports provides a significant leap forward compared with soluble enzyme assays by 
enabling the implementation of through-flow microreactors for, e.g. determination of time-
dependent inhibition. Immobilization of the complex CYP membrane-protein system is 
however particularly challenging as the preservation of the authentic enzyme kinetic 
parameters requires the full complexity of the lipid environment. The developed strategy is 
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bilayers to facilitate the gentle biotinylation of human liver microsomes (HLM) that 
incorporate all main natural CYP isoforms. The same process was also feasible for the 
biotinylation of recombinant CYPs expressed in insect cells, same as any membrane-bound 
enzymes in principle. As a result, CYPs could be immobilized on streptavidin-functionalized 
surfaces, both those of commercial magnetic beads and customized microfluidic arrays, so 
that the enzyme kinetic parameters remained unchanged, unlike in previously reported 
immobilization approaches that often suffer from restricted substrate diffusion to the 
enzyme’s active site and steric hindrances. The specificity and robustness of the 
functionalization method of customized microfluidic CYP assays was also carefully examined. 
 
Liposomes are widely utilized as nanocarriers in e.g. gene transfection[1] and drug delivery,[2] 
where cellular uptake is mainly governed by endocytosis. Certain, tailored, lipid compositions 
have been found to enable spontaneous bilayer fusion, the propensity of which is mainly 
promoted by the negative curvature[3] of the monolayer as well as by close contact, small size 
and unilamellarity of the liposomes.[4] Liposome fusion with cell membranes has been 
demonstrated using customized fusogenic liposomes (FL) comprising of neutral and 
positively charged lipids,[5] and a variety of cell-labeling approaches have been introduced for 
functionalization of mammalian cells with, e.g., fluorescent[6] or biotinylated lipids[7] or 
immune cell activating lipopolysaccharides.[8] In this work, we introduce a novel use for FLs, 
which facilitates a universal approach to immobilization of any membrane proteins on solid 
surfaces via the well-characterized avidin-biotin chemistry (Figure 1a). Here, we focused on 
the cytochrome P450 (CYP) system, the complexity of which places special demands on 
immobilization and has puzzled researchers for decades.[9] Mammalian CYPs are complex 
microsomal enzymatic systems consisting of both CYPs themselves as well as several 
electron-supplying redox partner enzymes, such as cytochrome P450 reductase,[10] embedded 
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constitute the majority of drug detoxification pathways,[12] and drug-drug interactions 
mediated by CYPs are thus the primary target of preclinical drug characterization. Human 
liver microsomes (HLM) are the preferred in vitro matrix, because they show CYP activities 
much higher than those of intact hepatocytes[13] and thus allow for high-throughput drug 
screening in vitro. By making use of the spontaneous fusion of customized biotinylated FL (b-
FL) with subcellular HLM fractions, we were able to biotinylate the HLMs in a natural and 
gentle manner and thus preserve the authentic enzyme kinetic functions of the membrane-
bound CYPs upon immobilization of the biotinylated HLMs on streptavidin-functionalized 
surfaces, both those of commercial microbeads and of customized microfluidic pillar arrays. 
 
CYP immobilization on solid support structures has raised considerable interest, since it 
would facilitate certain mechanistic and relative activity assays, such as time-dependent 
inhibition under continuous flow conditions, as well as more straightforward purification of 
the reaction products for both production and analytical purposes. The ability to manipulate 
substrate and inhibitor concentrations using flow chemistry additionally speeds up the 
determination of enzyme/inhibitor kinetics.[14] When further combined with the integration 
and parallelism possibilities of the emerging microarray technology, immobilized enzyme 
reactors (IMERs) would offer a compelling tool for high-throughput drug metabolism assays. 
However, the commonly applied enzyme immobilization strategies tend to result in diffusion-
limited mass transfer (e.g. physical entrapment of enzymes/microsomes[15]) or steric 
hindrance due to uncontrolled enzyme orientation (e.g. nonselective covalent bonding via 
amino acid residues[16]), which may result in flawed enzyme kinetic determinations and thus 
impair the in vitro-in vivo correlation.[17] Covalent immobilization may also alter the protein 
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The b-FL composition used in this study was modified from previous works[7,19] and 
contained both a (spacer-)biotinylated lipid (biotin-cap-1,2-dioleoyl-sn-glycero-3-
phophoethanolamine (DOPE), 0.1 m-%) and a fluorescent labeled lipid (Lissamine 
Rhodamine B-DOPE), 0.05 m-%) to facilitate not only immobilization of the biotinylated-
HLM (b-HLM) but also monitoring of the immobilization efficiency based on fluorescence. 
Prior to fusion with HLMs (37°C, 15 min), multilamellar liposomes of the given composition 
and average hydrodynamic radius of ca. 493 ±87 nm (Figure S1a) were prepared and 
extruded through a 100 nm membrane to yield unilamellar b-FLs with an average 
hydrodynamic radius of 220 ±25 nm (n=4 batches) (Figure S1b). Upon mixing, the opposite 
net charges of HLM (-44.3±4.9 mV, Figure S2) and b-FL (69.3±1.8 mV) promoted close 
contact via electrostatic inter-actions, facilitating membrane fusion. As expected, the 
biotinylation process did not significantly affect the activity of soluble CYP (Figure S3 and 
Figure S4), since the membrane fusion is a gentle process and the biotin label is small and 
locates in the lipid membrane considerably far from the enzyme’s active site. Also upon 
immobilization on streptavidin-functionalized magnetic beads, the enzyme affinities (KM) of 
four main CYP isoforms were similar to those of the soluble enzymes (Figure 1b and Figure 
S5) and the enzyme activities of the immobilized enzymes were preserved over at least 15 
days (Figure 1c). These results confirmed that by embedding the biotin in the lipid membrane 
for anchoring the HLMs on avidin-functionalized surfaces leaves the CYPs’ active sites 
accessible better than by covalent bonding of the CYP enzyme itself (as in, e.g. [16a]). Our 
approach also allows unhampered mass transfer to and from the enzyme’s active site (unlike 
in, e.g. [15a]) providing clear advantages over other previously reported immobilization 
approaches based on enzyme entrapment or covalent bonding. Moreover, no significant loss 
of CYP activity was observed with immobilized b-HLMs even after two weeks of storing at 
4°C, whereas negative controls prepared by solubilizing nonbiotinylated HLMs on lipid-
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use of the same batch of beads, the CYP activity was typically halved in all cases (Figure 1c), 
which likely resulted from incomplete recovery of the beads in subsequent incubations. 
Similar activity loss of CYPs immobilized on magnetic particles was also reported by 
Schejbal et al. [16b] 
 
To address the limitations related to handling and packing of magnetic beads, we further 
developed the concept toward implementation of microfluidic through-flow IMERs. The 
microfluidic IMERs were fabricated using a custom composition of thiol-enes, which are an 
emerging class of polymers facilitating low-cost microfabrication via non-cleanroom replica-
molding (Figure S6) based on UV-induced thiol-ene click chemistry.[20] By mixing the thiol 
or allyl monomers in off-stoichiometric ratios, the thiol-ene surfaces can be readily 
(bio)functionalized to incorporate excess of either free thiol or allyl functional groups.[21] In 
this work, thiol-rich surfaces were prepared and biotinylated with biotin-PEG4-alkyne via yet 
another UV induced thiol-yne reaction, followed by functionalization with fluorescent StrA 
(ex 488 nm) and eventually with b-HLM. As a preliminary characterization, we determined 
the water contact angles at each step of the functionalization protocol and observed that the 
functionalization resulted in clear changes in the surface wettability (Figure 2a). To maximize 
the surface area, and thus, the amount of immobilized CYP, we implemented a dense 
micropillar array[22] at the reaction zone (Figure 2a). Compared with porous polymer monolith 
packings, commonly used for enzyme immobilization in capillaries,[23] the micropillar arrays 
are less prone to clogging and reproducibility issues, and thus provide a convenient approach 
to implementation of well-ordered IMERs by microfabrication means. The robustness of the 
functionalization protocol was determined with respect to the effects of the bulk monomer 
(thiol/allyl) ratio and biotin and StrA concentrations on the amounts of immobilized StrA and 
b-HLM, which were quantitated based on their fluorescence tags (Figure 2b-d). As expected, 
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altered by adjusting either the number of free surface thiols (Figure 2b) or the biotin 
concentration (Figure 2c). The amount of immobilized b-HLM was, however, inversely 
dependent on the amount of bound StrA (Figure 2d). This likely resulted from more efficient 
biotin-streptavidin interactions in the absence of steric hindrances caused by excess 
streptavidin. For further assays, we used 0.1 mM biotin and 0.5 mg mL-1 StrA concentrations 
and a 25 mol-% excess of thiol functional groups in the bulk. 
 
The CYP activities of the IMERs were determined at a flow rate of 5 µL min-1 using 
temperature-insensitive Luciferin-H (200 µM in PBS) hydroxylation via CYP2C9 (Figure 3a) 
and temperature-sensitive coumarin (50 µM in 0.1 M Tris buffer) 7-hydroxylation via 
CYP2A6 (Figure 3b) as the model activities. In both cases, the IMERs maintained their CYP 
activity for at least 60 min, while the reaction temperature was shown to have an effect on the 
efficiency of the latter reaction, as expected. The developed method was also shown to be 
feasible for immobilization of recombinant CYPs (rCYPs) expressed in baculovirus-
transfected insect cells (Figure 3a), which highlights the universal nature of the developed 
enzyme immobilization strategy. Since our approach targets the lipid membrane, not the 
protein itself, it is universally applicable to biotinylation and immobilization of any 
membrane-bound protein on any avidin-coated surface. Finally, the specificity of the 
functionalization protocol was determined by omitting each of the functionalization steps at a 
time and determining the cumulative (60 min) amount of produced metabolite using three 
parallel IMERs in each condition. Although some traces of nonspecific binding of both StrA 
and b-HLM was observed in the fluorescence measurements, the activities of the CYP-IMERs 
prepared using the optimized functionalization protocol were significantly higher than those 
of any of the negative controls (Figure 3c), suggesting that the nonspecifically adsorbed lipid 
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On the basis of these results, the developed immobilization method, which is based on natural 
membrane fusion between biotinylated fusogenic liposomes and the desired lipid membrane 
incorporating the enzymes of interest, provides a universal tool for studying membrane-bound 
enzymes on solid surfaces. Furthermore, the thiol-ene click chemistry -based microchip 
fabrication and functionalization protocol, specifically used in this study, further provides a 
robust tool for implementation of through-flow IMERs for drug metabolism research. 
Efficient immobilization of the CYP system combined with the advantages of the microarray 
technology pave the way to novel methodologies, such as mechanistic drug inhibition studies. 
The concept developed herein is particularly suitable for applications where unaltered enzyme 
kinetics are of paramount importance, such as the preclinical drug screening and prediction of 
the in vivo drug response on the basis of in vitro enzyme kinetic results. 
 
 
Experimental Section  
Liposome preparation and fusion with human liver microsomes or recombinant cytochrome 
P450: Biotin-containing fusogenic liposomes (b-FL) were prepared using a lipid composition 
modified from Hersch et al.[7] and Csiszár et al.[9] by mixing stock solutions (in chloroform) of 
DOPE (10 mg mL-1), DOTAP (10 mg mL-1), biotin-cap-DOPE (10 mg mL-1) and Lissamine 
Rhodamine B-DOPE (1 mg mL-1) in a lipid mass ratio of 1:1:0.1:0.05, respectively. After 
mixing, the bulk solvent was evaporated under a stream of nitrogen. To remove any solvent 
residues, the lipid mixture was kept in vacuum for 2 h. Next, the dry lipid film was solvated in 
PBS to yield a total lipid concentration of 2 mg mL-1 and vortexed for 1 h at room 
temperature. To prepare unilamellar vesicles, the multilamellar liposome mixture was passed 
through a polycarbonate membrane (pore size 100 nm) 51 times using a benchtop extruder 
(Avanti Polar Lipids, Alabaster, AL). The size distribution of multilamellar and unilamellar b-
FLs  (Figure S1) was determined by dynamic light scattering (DLS) using Zetasizer APS and 
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determined using Zetasizer Nano ZS (both devices from Malvern, Worcestershire, UK). 
Before measurements, the HLM stock (20 mg mL-1 total protein) was diluted to a 
concentration of 0.125 mg mL-1 and the b-FL stock to a concentration of 0.002 mg mL-1 with 
de-ionized water. The b-FL dispersion was stored at ≤4°C until use. For HLM 
immobilization, equal volumes of the b-FL dispersion (2 mg mL-1 total lipid) and the HLM 
stock solution (20 mg mL-1 total protein) were mixed and incubated at 37°C for 15 min before 
applying the biotinylated HLM (b-HLM) vesicles onto the streptavidin functionalized 
magnetic beads or microchips. The recombinant cytochrome P450 (rCYP) isoenzymes were 
biotinylated in a similar manner by mixing the b-FL stock with an equal volume of the 
rCYP3A4, rCYP2D6 or rCYP2C9 stock (each 1 000 nmol L-1) followed by incubation at 
37°C for 15 min. 
Enzyme immobilization on streptavidin functionalized magnetic beads: Desired amount of 
streptavidin prefunctionalized, superparamagnetic beads (Dynabeads™ M-280, 10 mg mL-1, 
Life Technologies) was pre-treated according to the supplier’s protocol.[24] Next, the beads 
were divided in 25 µL aliquots (corresponding to 0.25 mg of beads) of which the supernatant 
was separated and discarded. The b-HLM vesicles (15 L) were immediately added onto the 
beads and the suspension was incubated on a tube rotator at room temperature for 30 min, 
after which the supernatant was discarded and the beads were washed 4–5 times with 50 µL 
of PBS using magnetic separation. After functionalization, the beads were stored in 50 µL of 
PBS at ≤4°C until use. In addition to b-HLM vesicles, the pretreated beads were also 
functionalized with biotinylated DPPE lipids and then with bare HLM vesicles (negative 
control), as described in the Supporting Information.  
Microchip fabrication and biofunctionalization: The immobilized enzyme microreactors 
(IMERs) were implemented on micropillar arrays that were fabricated in-house and 
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fabricated from thiol-ene polymers following a previously developed protocol.[22] The 
microreactor design comprised a 30-mm-long and 4-mm-wide microchannel featuring an 
array of ca. 13 600 micropillars (Ø 60 µm) (Figure 2a). The channel height was 200 µm and 
the total chip volume ca. 25 µL (including the connecting channels between inlet/outlet and 
excluding the space occupied by the micropillars). The chip fabrication protocol included four 
steps: (i) SU-8 master fabrication in cleanroom conditions, (ii) casting of a PDMS mold using 
the SU-8 master as a template, (iii) UV replica-molding of the microchannel and the cover 
layers out of thiol-ene polymers using the PDMS mold, and (iv) bonding of the two thiol-ene 
layers by lamination (Figure S6). The cleanroom fabrication of the SU-8 masters (step i) is 
described in the Supporting Information. The PDMS molds (step ii) were prepared by mixing 
the base elastomer and the curing agent in a ratio of 10:1 or 9:1 (w/w), degassing in vacuum 
for 30 min, and pouring the mixture onto the SU-8 master prior to curing by heat (80°C for 3h 
or 65°C overnight). The thiol-ene layers (step iii) were prepared by mixing tetrathiol and 
triallyl monomers in a molar ratio of 3:2 (with respect to free thiol and allyl functional 
groups), which resulted in thiol-rich (25 mol-% excess of thiols) bulk composition. In 
addition, stoichiometric compositions (tetrathiol and triallyl monomers mixed in a molar ratio 
resulting in equal amounts free thiol and allyl functional groups) were used as controls during 
the validation of the biofunctionalization process. Next, the monomer mixture was poured 
onto the PDMS mold, degassed in vacuum, and cured under UV for 5 min (Dymax 5000-EC 
Series UV flood exposure lamp, nominal power 225 mW cm-2, Dymax Corporation, 
Torrington, CT). Both microchannel and cover layers (with inlet/outlet holes) were prepared 
in the same manner. The two, preheated (70°C) layers were laminated together and exposed to 
UV for an additional 2 min (step iv). The average amount of free surface thiols was 
determined by titration with Ellman’s reagent and was, for instance, 133±13 nm-2 when 50 
mol-% excess of thiol functional groups was used in the bulk composition. Finally, the thiol-
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et al.[21a] Briefly, free surface thiols were functionalized with biotinylated PEG4-alkyne 
(0.1 mM in ethylene glycol with 1% Igracure TPO-L as the photoinitiator) using 
photopolymerization under UV (λ = 365 nm) for 1–2 min (Figure 2a). Next, the microreactor 
was thoroughly rinsed sequentially with methanol and deionized water (≥5 mL each) and 
filled with 0.5 mg mL-1 Alexa Fluor® Streptavidin in PBS. After incubation at room 
temperature for 30–45 min, the microreactor was again thoroughly rinsed with PBS (≥5 mL) 
and filled with the b-HLM vesicles or biotinylated rCYPs. Finally, after incubation at ≤4°C 
overnight (b-HLM) or at room temperature for 30 min (biotinylated rCYP), the microreactor 
was thoroughly rinsed with PBS (≥5 mL) and used immediately. For validation of the surface 
biofunctionalization process, controls were prepared using varying biotin (0.01–1 mM) and 
streptavidin (0.005–0.5 mg mL-1) concentrations and characterized in terms of the efficiency 
of streptavidin and b-HLM immobilization by fluorescence (for details, see Supporting 
Information). The success of the surface modifications were also monitored based on changes 
of the water contact angle (for details, see Supporting Information) compared to that of native 
thiol-ene surface (Figure 2a). 
CYP incubations with enzymes immobilized on magnetic beads: The CYPs immobilized on 
magnetic beads were incubated in Eppendorf tubes similar to soluble enzymes (see 
Supporting Information) with the following exceptions: Instead of the specified amount of 
HLM (see Table S1), 0.25 mg of magnetic beads incorporating the immobilized CYPs were 
added to each reaction and preincubated with the substrate prior to addition of NADPH. The 
reactions were stopped by separating the beads from the supernatant using an external magnet. 
After reaction, the beads were washed twice with PBS buffer (50 µL) and stored (in PBS 
buffer) at ≤4°C until further use. The supernatants (100 µL) were either acidified for 
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with the Luciferin detection reagent (100 µL) for luminescence detection (all other CYP 
isoforms). 
CYP incubations on immobilized enzyme microreactors: The CYP activity of the IMERs was 
assessed by infusing the substrate solution containing NADPH (0.1 mM, in the specified 
buffer) through the IMER at a flow rate of 5 µL min-1 and collecting fractions of 50 or 100 µL 
of the outcome for further (off-line) analysis. The collected fractions were either acidified or 
allowed to react with the luminescence detection reagent as previously specified. For 
reactions conducted at physiological temperatures, the IMERs were heated using a resistive 
heater (R=0.5 Ω, P=0.6–0.8W) connected to an external power supply. The temperature on 
the top surface of the IMER was measured with a thermocouple and adjusted to 35°C 
(corresponding to roughly two degrees higher temperature inside the microchannel on the 
basis of a prior publication[25]) using a PID-controller connected to the circuit. 
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Figure 1. Immobilization of human liver microsomes (HLM) on streptavidin-functionalized 
magnetic particles using fusogenic liposomes. a) A schematic describing the immobilization 
protocol. b) Isoenzyme-specific KM values of four main CYPs, when immobilized on 
magnetic beads, compared to values determined for the same isoenzymes incorporated in 
soluble HLM. c) Relative activity (percentage of initial activity on day 0) of b-HLM 
immobilized on magnetic particles (n=4 batches each) on consecutive incubation cycles (1.–










































































Figure 2. Development of CYP-IMERs utilizing immobilization via fusogenic liposomes. a) 
Photograph of the thiol-ene micropillar chip, scanning electron microscope (SEM) image of 
the micropillar array and a schematic of the biotin-streptavidin functionalization of the thiol-
ene pillars with inlays of fluorescence microscopy pictures and water contact angle 
measurements of thiol-ene surfaces (25% molar excess of thiol monomer in the bulk) after 
each step of the functionalization protocol. The effect of b) thiol-ene molar ratio, c) biotin and 
d) streptavidin concentration on the binding efficiency of streptavidin (StrA) and biotinylated 
fusogenic liposomes (b-FL) on thiol-ene micropillar surfaces as quantified (n=3 IMERs) by 




Figure 3. Figure 3. Characterization of CYP-IMER performance. a) Relative activity of CYP-
IMERs immobilized with HLM (n=3) and two recombinant CYP enzymes (n=2 each) as a 
function of time. b) Relative CYP2A6 activity of CYP-IMERs as a function of time in room 
temperature and 37°C as percentage of the initial activity at 37°C. c) Cumulative metabolite 
production (60 min) of CYP-IMERs (n=3) prepared by sequentially omitting all the steps in 
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Immobilization of membrane-bound enzymes, such as the drug-metabolizing cytochromes 
P450 (CYPs), is facilitated by a novel, nanotechnology inspired immobilization method 
utilizing membrane biotinylation via customized fusogenic liposomes. Unlike in previously 
reported immobilization approaches, the kinetic characteristics of CYPs remain unchanged 
using the developed method. 
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Overcoming the Pitfalls of Cytochrome P450 Immobilization Through the Use of 
Fusogenic Liposomes 
 




Materials and methods 
 
Materials and reagents: 7-hydroxycoumarin, β-nicotinamide adenine dinucleotide 2′-
phosphate (NADPH) reduced tetrasodium salt hydrate, biotin-PEG4-alkyne, coumarin, 
Trizma® base and phosphate buffered saline (PBS, pH 7.4) were purchased from Sigma 
Aldrich, St. Louis, MO. Perchloric acid (HClO4) and magnesium chloride (MgCl2) were from 
Riedel-de-Haën, Seelze, Germany. Irgacure® TPO-L (Ethyl phenyl(2,4,6-
trimethylbenzoyl)phosphinate (84434-11-7) photoinitiator was from BASF, Ludwigshafen, 
Germany. Streptavidin (Alexa Fluor® 488 conjugate) was from Life Technologies, Eugene, 
OR. All chemicals were of analytical grade unless otherwise stated. Deionized water was 
purified with a Milli-Q water purification system (Millipore, Molsheim, France). The 
luminescent cytochrome P450 (CYP) substrates (P450-Glo™ assays), Luciferin-IPA 
(CYP3A4), Luciferin-ME EGE (CYP2D6), Luciferin-H (CYP2C9), and the Luciferin 
detection reagent were purchased from Promega, Madison, WI. The human liver microsome 
(HLM) preparation used (as the source of CYP activity) was Corning® Gentest 20-Donor 
Pool (BD Biosciences, Woburn, MA). Recombinant isoenzymes used (CYP3A4, CYP2D6 
and CYP2C9) were of Corning® Supersomes™ series (BD Biosciences, Woburn, MA). All 
lipids used in the study were from Avanti Polar Lipids, Alabaster, AL: 1,2-dioleoyl-3-
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(Cap biotinyl) (sodium salt) (biotin-cap-DOPE), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Lissamine 
Rhodamine B-DOPE). The magnetic particles used in this study were commercial 
paramagnetic beads (Dynabeads® M-280, Ø = 2.8 μm, ~6–7 × 108 beads per mL) 
manufactured by Life Technologies, Oslo, Norway. The monomers used for microchip 
fabrication, pentaerythritol tetrakis(3-mercaptopropionate) (‘tetrathiol’) (≥95.0%) and 1,3,5-
triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)- trione (‘triene’) (≥98.0%), were purchased from 
Sigma–Aldrich (Saint Louis, MO). Poly(dimethyl siloxane) (PDMS) was prepared by mixing 
Sylgard 184 base elastomer and curing agent in a 10:1 or 9:1 (w/w) ratio (Down Corning 
Corporation, Midland, MI). 
Fabrication of SU-8 masters: For fabrication of the SU-8 masters (step i of the chip 
fabrication protocol), silicon wafers were first dipped into hydrofluoric acid to improve 
photoresist adhesion. SU-8 100 (Micro Resist Technology, Germany) was spin coated (1700 
rpm, 30 s) and soft baked on a hotplate (65°C for 25 min followed by 95°C for 3.5 h) to yield 
a 200-m-thick SU-8 layer, which was then UV exposed with a dose of 0.63 J cm-2 on the 
MA-6 mask aligner (Süss Microtec, Garching, Germany). Post exposure bake was done on a 
hotplate (65°C for 1 h followed by a slow 4-hour ramp back to room temperature) and the 
development in propylene glycol methyl ether acetate for 75 min. After development, the 
master was hard baked on the hotplate at 150°C for 3 h. Finally, the master was coated by a 
nominally 40-nm-thick fluoropolymer layer for anti-adhesion. The fluoropolymer was 
deposited by plasma-enhanced chemical vapor deposition (PECVD) (Plasmalab 80+, Oxford 
Instruments, UK), out of the trifluoromethane (CHF3) precursor. 
Control functionalizations of magnetic particles: For functionalization with biotinylated 
DPPE lipids, 400 µL (4 mg) of the pretreated beads in PBS were added to the evaporated 
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lipid-functionalized beads were divided in 25 µL aliquots and 15 µL of bare HLM vesicles 
(10 mg mL-1 total protein in 0.1 M Tris, pH 7.5, containing 3.3 mM MgCl2 and 1% Pluronic 
F127) was added to each sample. After incubation at room temperature for 30 min, the 
supernatant was discarded and the beads were washed 4–5 times with 50 µL of PBS using 
magnetic separation and stored in 50 µL of PBS at ≤4°C until use. 
CYP model activities and enzyme incubation conditions: The CYP model activities (probe 
substrates and their metabolites) are listed in Table S1 along with the isoenzyme-specific 
incubation conditions (selection of buffer, amount of HLM, incubation time).  
CYP incubations with soluble enzymes: The CYP (control) incubations were conducted in 
Eppendorf tubes at 37°C at a total volume of 100 µL using NADPH (1 mM) as the cofactor. 
The selected CYP model activities were determined using isoenzyme-specific probe 
substrates as described in Table S1. The incubation buffer, the amount of HLM, and the 
incubation time were adjusted isoenzyme specifically so that the model activities followed 
Michaelis-Menten kinetics (see Table S1). Prior to initiating the reaction by the addition of 
NADPH, the HLM and the substrate were mixed and preincubated at 37°C for 5 min. The 
CYP2A6 reactions were stopped by the addition of 10 µL of ice-cold perchloric acid (4 M), 
after which the samples were kept on ice for 20 min, centrifuged at 16 000 g for 10 min, and 
the supernatants were transferred for fluorescence analysis (ex 325 nm, em 470 nm). All other 
CYP reactions were stopped by the addition of the Luciferin detection reagent (100 µL), 
incubated at room temperature for 20 min and analyzed for luminescence. The fluorescence 
and luminescence measurements were carried out on a Varioskan Flash or a Varioskan LUX 
microplate reader (both from Thermo Scientific, Vantaa, Finland). To ensure that the 
enzymatic activity of HLM is not degraded during the incubation steps of the immobilization 
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storing/incubation at 4°C, room temperature and 37°C for given periods of time (Figure S3). 
Based on the results, CYP activity is not compromised during the immobilization process.  
Fluorescence measurements: The reaction mixtures from CYP-IMERs or magnetic bead CYP 
assays were analyzed with a Varioskan Flash or Varioskan LUX well plate reader using either 
fluorescence (CYP2A6, ex 325/em 470 nm, bandwidth 12 nm, measurement time 100 ms) or 
luminescence (CYP2C9, CYP2D6 and CYP3A4) spectroscopy. The binding of streptavidin 
and the immobilization efficiency of b-HLM vesicles and biotinylated rCYPs on thiol-ene 
microchannels was monitored on a Zeiss AxioScope A1 upright epifluorescence microscope 
(Zeiss Finland, Espoo, Finland) equipped with a Plan-Neofluar 20✕/0.4 Corr objective and a 
HAL100 halogen lamp (100W). The fluorescence signal of streptavidin and lissamine 
rhodamine B (ex 488/em 500–700 nm and ex 546±6 nm, em 575–640 nm, respectively) was 
monitored using a Moticam 3500 color CCD camera (Motic, Xiamen, China) or quantified 
using a Hamamatsu R5929 photomultiplier tube equipped with a signal amplifier module 
(Cairn Research, Faversham, UK) and a PicoScope 2203 AD converter (Pico Technology, St. 
Neots, UK). 
Water contact angle measurements: The wetting properties of thiol-ene surfaces after 
different functionalization steps were characterized by a sessile water drop contact angle 
method.[1] Water drop profiles were recorded with an optical contact angle and surface tension 
meter (KSV Instruments Ltd., Helsinki, Finland) equipped with a camera (CAM 200, 30 fps). 
To determine the water contact angle (WCA), three drops of Milli-Q water were placed 
randomly over the surface and the contact angle was determined by processing the images 
with Attension Theta software (Version 4.1.0) and averaged. 
Scanning electron microscope: Scanning electron microscope (SEM, FEI Quanta™ FEG, 
Hillsboro, OR) was used for characterization of the micropillar arrays. Samples were attached 
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(Quorum Q150TS, turbomolecular-pumped high resolution coater, Quorum Technologies, 






































































Supplementary figures and tables 
 
 
Table S1. CYP model activities and incubation conditions used in the study. 










[S] used for Michaelis 














Tris (0.1M, pH 7.5)  
+ 3.3 mM MgCl2 
Potassium phosphate (0.1M, pH 7.4) 
HLM (total protein) 0.4 mg mL-1 0.4 mg mL-1 0.4 mg mL-1 0.2 mg mL-1 
Incubation time (@ 37°C) 15 min 30 min 30 min 10 min 
Stop reagent 
4M perchloric acid  
(+10 µL per reaction) 
Luciferin detection reagent  
(+100 µL per reaction) 
Detection 
fluorescence  
ex 325 nm/em 470 nm 
luminescence(b) 
a)The CYP2D6 incubations were carried out in the presence of 5 µM furafylline (inhibitor of CYP1A1 
and CYP1A2 isoenzyme activity) due to limited specificity of Luciferin-ME EGE to CYP2D6. 
b)CYP enzymes act on a luminogenic proluciferin to produce a luciferin product that generates light 
upon reaction with luciferase, which is added after the CYP reaction has been completed. The CYP 







































































Figure S1. Size distribution of fusogenic liposome dispersion by dynamic light scattering 
(DLS) a) before extrusion b) after extrusion (51x through a 100 nm membrane). Extrusion of 
the liposome dispersion resulted in a significant decrease in both average liposome size (Z-
average size of 662 nm vs 241 nm) and polydispersity (polydispersity index, PDI) of 0.176 vs 
0.094). The results shown are means from three repeated runs of 13 measurements on the 
same sample. It should be noted that because the z-average gives only a single average value 
for the whole particle population, it does not accurately describe the size distribution of the 
polydisperse nonextruded sample. The zeta potential of the fusogenic liposomes was 







































































Figure S2. Vesicle size distribution of HLM (0.125 mg mL-1 in deionized water) by DLS. 
The vesicle size distribution showed three distinct fractions with average vesicle diameters of 
150 nm, 1000 nm, and 5000 nm. As the scattering intensity is proportional to the sixth power 
of the particle diameter, scattering from large particles may easily suppress signals from 
smaller particles.[2] Taking this into account, the quantity of the smallest vesicles (size fraction 
in the range of 100–200 nm) is much more than what can be directly inferred from the data. 







































































Figure S3. Relative activity of HLM stored for given periods of time at a) room temperature 







































































Figure S4. The relative activity of HLM and biotinylated HLM (both in soluble form, 
nonimmobilized) as a function of time. The initial activity of nonbiotinylated HLM is used as 
the reference point for the relative activities of both HLM and biotinylated HLM. Data points 










































































Figure S5. Michaelis-Menten curves for four CYP isoforms determined with soluble HLM, 
b-HLM immobilized on streptavidin-coated magnetic particles and HLM solubilized on lipid-
functionalized magnetic particles (control). For CYP3A4, a sigmoidal fit was chosen based on 
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